OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
ADAM VTE & Ibrutinib CV Toxicity
18 minutes
Posted Oct 24, 2019 at 7:27 pm.
0:00
18:10
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
ADAM VTE (apixaban for cancer-associated VTE) results have been published - let's talk about it. Also, what are the implications of long term ibrutinib on CV health? A new Blood paper offers some possible answers.
Previous
To Rechallenge, Or Not To Rechallenge
Next
Carboplatin
← See all 273 episodes of OncoPharm